ZANTAC 300 Drug Patent Profile
✉ Email this page to a colleague
When do Zantac 300 patents expire, and when can generic versions of Zantac 300 launch?
Zantac 300 is a drug marketed by Glaxosmithkline and Glaxo Grp Ltd and is included in two NDAs.
The generic ingredient in ZANTAC 300 is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zantac 300
A generic version of ZANTAC 300 was approved as ranitidine hydrochloride by SANDOZ on August 29th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZANTAC 300?
- What are the global sales for ZANTAC 300?
- What is Average Wholesale Price for ZANTAC 300?
Summary for ZANTAC 300
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 35 |
Clinical Trials: | 22 |
Patent Applications: | 2,331 |
DailyMed Link: | ZANTAC 300 at DailyMed |
Recent Clinical Trials for ZANTAC 300
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Spaulding Clinical Research LLC | Phase 1 |
Food and Drug Administration (FDA) | Phase 1 |
Nova Scotia Health Authority | Phase 4 |
US Patents and Regulatory Information for ZANTAC 300
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | ZANTAC 300 | ranitidine hydrochloride | CAPSULE;ORAL | 020095-002 | Mar 8, 1994 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Glaxo Grp Ltd | ZANTAC 300 | ranitidine hydrochloride | TABLET;ORAL | 018703-002 | Dec 9, 1985 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZANTAC 300
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxo Grp Ltd | ZANTAC 300 | ranitidine hydrochloride | TABLET;ORAL | 018703-002 | Dec 9, 1985 | 4,521,431*PED | ⤷ Subscribe |
Glaxosmithkline | ZANTAC 300 | ranitidine hydrochloride | CAPSULE;ORAL | 020095-002 | Mar 8, 1994 | 4,128,658 | ⤷ Subscribe |
Glaxo Grp Ltd | ZANTAC 300 | ranitidine hydrochloride | TABLET;ORAL | 018703-002 | Dec 9, 1985 | 4,880,636*PED | ⤷ Subscribe |
Glaxo Grp Ltd | ZANTAC 300 | ranitidine hydrochloride | TABLET;ORAL | 018703-002 | Dec 9, 1985 | 4,128,658 | ⤷ Subscribe |
Glaxosmithkline | ZANTAC 300 | ranitidine hydrochloride | CAPSULE;ORAL | 020095-002 | Mar 8, 1994 | 5,028,432*PED | ⤷ Subscribe |
Glaxosmithkline | ZANTAC 300 | ranitidine hydrochloride | CAPSULE;ORAL | 020095-002 | Mar 8, 1994 | 4,521,431*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZANTAC 300
See the table below for patents covering ZANTAC 300 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 8916275 | ⤷ Subscribe | |
Spain | 505951 | ⤷ Subscribe | |
France | 2643263 | COMPOSITION PHARMACEUTIQUE A BASE DE RANITIDINE | ⤷ Subscribe |
Germany | 2734070 | ⤷ Subscribe | |
Japan | H0443070 | ⤷ Subscribe | |
Yugoslavia | 40088 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
ZANTAC 300 Market Analysis and Financial Projection Experimental
More… ↓